Trial Profile

An Open-Label, Phase 1, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CMG901 in Subjects With Advanced Unresectable or Metastatic Solid Tumor

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 06 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CMG 901 (Primary)
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors KeyMed Biosciences

26 Mar 2025 According to Keymed Biosciences media release, on 6 Jan, data from the Phase I clinical study was released on the international authoritative oncology journal, The Lancet Oncology.
26 Mar 2025 According to Keymed Biosciences media release, data from this study were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024.
12 Feb 2025 Status changed from recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com